Biocon Limited
NSE: BIOCON BSE: BIOCON
Prev Close
398.15
Open Price
400
Volume
6,133,205
Today Low / High
394.4 / 403
52 WK Low / High
291 / 406
Range
377 - 417
Prev Close
398.3
Open Price
399
Volume
200,868
Today Low / High
394.2 / 403.15
52 WK Low / High
290.8 / 405.9
Range
377 - 417
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 397.3 (target range: 377 - 417), reflecting a change of -0.85 (-0.21349%). On the BSE, it is listed at 397.3 (target range: 377 - 417), showing a change of -1 (-0.25107%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Biocon Limited Graph
Biocon Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Biocon Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 397.30, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 397.30 | 401.27 | 361.15 - 441.40 |
| 405.25 | 324.20 - 486.30 | ||
| 409.22 | 286.45 - 531.98 | ||
| Bearish Scenario | 397.30 | 393.33 | 353.99 - 432.66 |
| 389.35 | 311.48 - 467.22 | ||
| 385.38 | 269.77 - 501.00 |
Overview of Biocon Limited
ISIN
INE376G01013
Industry
Biotechnology
Vol.Avg
4,721,198
Market Cap
530,166,288,889
Last Dividend
0.5
Official Website
IPO Date
2004-04-07
DCF Diff
305.52
DCF
92
Financial Ratios Every Investor Needs
Stock Dividend of BIOCON
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-04 | July 04, 25 | 0.5 | 0.5 | 2025-07-04 | 2025-08-22 | |
| 2024-07-05 | July 05, 24 | 0.5 | 0.5 | 2024-07-05 | 2024-08-23 | |
| 2023-07-07 | July 07, 23 | 1.5 | 1.5 | 2023-07-07 | 2023-09-08 | |
| 2022-06-30 | June 30, 22 | 0.5 | 0.5 | 2022-07-01 | 2022-08-28 | |
| 2019-07-18 | July 18, 19 | 0.5 | 0.5 | 2019-07-19 | 2019-08-02 | 2019-04-25 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 15,052.20 Cr | 5,197.50 Cr | 9,854.70 Cr | 0.6547 | 147.60 Cr | 0.00 Cr | 1,331.70 Cr | 1,013.30 Cr | 8.46 | 4,471.00 Cr | 0.0673 |
| 2024-03-31 | 14,755.70 Cr | 5,582.20 Cr | 9,173.50 Cr | 0.6217 | 1,237.80 Cr | 2,665.50 Cr | 5,083.20 Cr | 1,022.50 Cr | 8.55 | 4,152.60 Cr | 0.0693 |
| 2023-03-31 | 11,174.20 Cr | 3,663.10 Cr | 7,511.10 Cr | 0.6722 | 613.20 Cr | 265.10 Cr | 1,564.30 Cr | 462.70 Cr | 3.88 | 2,596.20 Cr | 0.0414 |
| 2022-03-31 | 8,024.80 Cr | 2,723.60 Cr | 5,301.20 Cr | 0.6606 | 502.80 Cr | 186.90 Cr | 1,158.30 Cr | 648.40 Cr | 5.44 | 2,071.80 Cr | 0.0808 |
| 2021-03-31 | 6,970.10 Cr | 2,210.20 Cr | 4,759.90 Cr | 0.6829 | 395.00 Cr | 252.90 Cr | 953.90 Cr | 740.50 Cr | 6.24 | 1,919.90 Cr | 0.1062 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3,227.10 Cr | 58,797.30 Cr | 31,084.80 Cr | 21,644.0000 Cr | 18,362.00 Cr | 15,134.90 Cr | 4,931.10 Cr | 13,414.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 14,333.8000 Cr |
| 2024-03-31 | 1,233.40 Cr | 56,070.70 Cr | 30,795.90 Cr | 19,783.7000 Cr | 16,276.70 Cr | 15,043.30 Cr | 4,943.90 Cr | 11,977.80 Cr | 634.10 Cr | 310.70 Cr | 0.00 Cr | 15,358.8000 Cr |
| 2023-03-31 | 1,323.50 Cr | 52,042.80 Cr | 29,554.00 Cr | 17,866.9000 Cr | 18,018.80 Cr | 16,695.30 Cr | 4,243.70 Cr | 10,122.60 Cr | 899.00 Cr | 290.10 Cr | 867.30 Cr | 8,510.7000 Cr |
| 2022-03-31 | 662.60 Cr | 20,394.00 Cr | 10,924.00 Cr | 8,432.5000 Cr | 5,146.60 Cr | 4,484.00 Cr | 2,298.20 Cr | 9,415.50 Cr | 1,260.90 Cr | 1,215.10 Cr | 370.20 Cr | 3,828.0000 Cr |
| 2021-03-31 | 952.60 Cr | 18,522.30 Cr | 10,014.70 Cr | 7,626.9000 Cr | 4,481.10 Cr | 3,528.50 Cr | 1,866.60 Cr | 7,964.10 Cr | 1,261.50 Cr | 1,025.30 Cr | 882.10 Cr | 4,210.1000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,061.2000 Cr | -234.1000 Cr | -1,854.0000 Cr | 1,717.9000 Cr | 2,004.3000 Cr | 2,923.8000 Cr | -2,136.6000 Cr | 1,429.4000 Cr | 572.9000 Cr | -82.9000 Cr | -0.3000 Cr |
| 2024-03-31 | 2,953.9000 Cr | -1,004.5000 Cr | -2,332.7000 Cr | 1,022.3000 Cr | -380.4000 Cr | 919.5000 Cr | -1,931.6000 Cr | 1,022.5000 Cr | -1,271.2000 Cr | -203.0000 Cr | -886.4000 Cr |
| 2023-03-31 | 1,852.5000 Cr | -14,281.8000 Cr | 13,048.7000 Cr | 126.2000 Cr | 641.1000 Cr | 1,294.8000 Cr | -1,726.3000 Cr | 643.0000 Cr | 12,415.9000 Cr | -71.8000 Cr | 886.2000 Cr |
| 2022-03-31 | 1,176.6000 Cr | -1,699.1000 Cr | 242.1000 Cr | -748.2000 Cr | -243.3000 Cr | 653.7000 Cr | -1,924.8000 Cr | 771.6000 Cr | 321.3000 Cr | 0.0000 Cr | -414.0000 Cr |
| 2021-03-31 | 1,159.7000 Cr | -3,624.7000 Cr | 2,564.0000 Cr | -586.6000 Cr | 72.3000 Cr | 897.0000 Cr | -1,746.3000 Cr | 846.2000 Cr | 1,888.8000 Cr | 0.0000 Cr | -445.4000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,453.90 Cr | 1,472.90 Cr | 2,981.00 Cr | 0.6693 | 2,132.90 Cr | 344.50 Cr | 2.88 | 1,100.55 Cr | 0.0773 |
| 2024-12-31 | 3,773.00 Cr | 1,359.30 Cr | 2,413.70 Cr | 0.6397 | 292.30 Cr | 25.10 Cr | 0.21 | 804.70 Cr | 0.0067 |
| 2024-09-30 | 3,545.00 Cr | 1,182.60 Cr | 2,362.40 Cr | 0.6664 | 221.10 Cr | -16.00 Cr | -0.13 | 743.90 Cr | -0.0045 |
| 2024-06-30 | 3,432.90 Cr | 2,311.40 Cr | 1,121.50 Cr | 0.3267 | 215.00 Cr | 659.70 Cr | 5.49 | 620.40 Cr | 0.1922 |
| 2024-03-31 | 3,917.10 Cr | 2,404.40 Cr | 1,512.70 Cr | 0.3862 | 508.90 Cr | 135.50 Cr | 1.13 | 955.70 Cr | 0.0346 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3,227.10 Cr | 1,796.30 Cr | 5,023.40 Cr | 5,487.90 Cr | 4,931.10 Cr | 16,286.20 Cr | 13,414.10 Cr | 58,797.30 Cr | 31,084.80 Cr |
| 2024-12-31 | 2,569.00 Cr | 549.00 Cr | 2,650.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 58,013.00 Cr | 30,448.00 Cr |
| 2024-09-30 | 1,687.70 Cr | 1,429.50 Cr | 3,117.20 Cr | 6,129.20 Cr | 4,965.10 Cr | 15,153.50 Cr | 12,453.40 Cr | 57,127.90 Cr | 30,407.90 Cr |
| 2024-06-30 | 1,919.00 Cr | 814.00 Cr | 2,574.00 Cr | 0.00 Cr | 5,037.00 Cr | 2,574.00 Cr | 12,133.00 Cr | 55,671.00 Cr | -25,274.80 Cr |
| 2024-03-31 | 2,258.70 Cr | 315.60 Cr | 2,574.30 Cr | 6,230.60 Cr | 4,943.90 Cr | 15,179.20 Cr | 11,977.80 Cr | 56,070.70 Cr | 30,795.90 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 344.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 25.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -16.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 659.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 135.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-06-12 | June 12, 19 | 2:1 |
| 2017-06-15 | June 15, 17 | 3:1 |
| 2008-09-11 | September 11, 08 | 2:1 |
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹397.30 | ₹530,166,288,889.00 | ₹6,133,205.00 |
| Syngene International Limited | SYNGENE | ₹722.05 | ₹289,805,521,713.00 | ₹2,536,330.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹201.37 | ₹267,670,710,034.00 | ₹4,286,230.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,824.00 | ₹190,819,948,800.00 | ₹35,048.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹796.35 | ₹138,139,187,217.00 | ₹820,514.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹810.60 | ₹129,113,178,600.00 | ₹229,344.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹668.05 | ₹53,766,534,540.00 | ₹186,055.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹256.00 | ₹40,136,448,000.00 | ₹194,928.00 |
| Zota Health Care Limited | ZOTA | ₹1,234.85 | ₹36,383,002,975.00 | ₹56,295.00 |
Key Executives
Gender: male
Year Born:
Gender: female
Year Born: 1966
Gender: Not Specified
Year Born: 1953
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1978
Gender: male
Year Born:
Gender: female
Year Born: 1973
Gender: male
Year Born:
Gender: male
Year Born: 1973
FAQs about Biocon Limited
The CEO is Siddharth Mittal BCom, CA, CPA.
The current price is ₹397.30.
The range is ₹291-406.
The market capitalization is ₹53,016.63 crores.
The dividend yield is 0.13%.
The P/E ratio is 47.06.
The company operates in the Healthcare sector.
Overview of Biocon Limited (ISIN: INE376G01013) is a leading Biotechnology in India. With a market capitalization of ₹53,016.63 crores and an average daily volume of 4,721,198 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.5.